Search results for "Fibrosis"

showing 10 items of 901 documents

Immunohistochemical and morphological characteristics of tissues response to polylactic acid membranes with silver nanoparticles

2019

Background The aim of this research was to study anti-microbial and anti-inflammatory characteristics of silver nanoparticles helping bone structures to recover during late stage of parodontitis, which afterwards will increase the effect of bone regeneration operations. Material and Methods We assessed colloid solution-derived silver nanoparticles coating of polylactic acid membrane regarding tissue foreign body response. Thirty eight polylactic acid membranes were implanted intracranially in rabbits – ten unmodified (control group) and twenty eight with silver nanoparticles coating (experimental group). In controls, penicillin was used for infection prophylaxis. Tissue response was assesse…

Bone RegenerationSilverPolyestersMetal NanoparticlesNanoparticleSilver nanoparticleColloidchemistry.chemical_compoundPolylactic acidFibrosismedicineAnimalsBone regenerationGeneral DentistryOral Medicine and PathologyChemistryResearchCapsulemedicine.disease:CIENCIAS MÉDICAS [UNESCO]MembraneOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryRabbitsBiomedical engineering
researchProduct

The CFTR associated protein CAP70 interacts with the apical Cl-/HCO3- exchanger DRA in rabbit small intestinal mucosa.

2005

DRA (down regulated in adenoma) is an intestinal anion exchanger, acting in parallel with NHE3 to facilitate ileal and colonic NaCl absorption. Furthermore it is involved in small intestinal bicarbonate secretion. Because DRA has a PDZ interaction motif, which may influence its properties, we searched for DRA-interacting PDZ adapter proteins in the small intestine. Using an overlay assay with the recombinant DRA C-terminus as a ligand, a 70 kDa protein was labeled, which was restricted to the brush border membrane in rabbit duodenal and ileal mucosa and was not detected in the colon. Destruction of the C-terminal PDZ interaction motif abolished this band, suggesting a specific protein-prote…

Brush borderColonPDZ domainAmino Acid MotifsMolecular Sequence DataCystic Fibrosis Transmembrane Conductance RegulatorIleumBiologyBiochemistryAntiportersCell LineIntestine SmallmedicineAnimalsHumansSecretionAmino Acid SequenceChloride-Bicarbonate AntiportersRNA MessengerIntestinal MucosaMessenger RNAHEK 293 cellsSignal transducing adaptor proteinMembrane ProteinsMolecular biologySmall intestinePeptide Fragmentsmedicine.anatomical_structureSulfate TransportersRabbitsCarrier ProteinsBiochemistry
researchProduct

Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.

2006

AbstractTherapy of chronic respiratory diseases often involves inhalation therapy with nebulizers. Patients often attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. This article considers the issue of physico-chemical compatibility of admixtures of drug solutions/suspensions in nebulizers.A search of databases, prescribing information and primary literature was conducted to locate literature concerning the physico-chemical compatibility of inhalation solutions/suspensions. This was supplemented by telephone interviews.Admixtures of albuterol with ipratropium and/or cromolyn, of albuterol and budesonide, or tobramy…

BudesonideDrugPulmonary and Respiratory MedicineRespiratory TherapyCystic Fibrosismedia_common.quotation_subjectReviewCompatibilityBenzalkonium chlorideAdministration InhalationCromolyn SodiummedicineDeoxyribonuclease IHumansAlbuterolPediatrics Perinatology and Child HealthAnti-Asthmatic AgentsBudesonideFenoterolmedia_commonExpectorantsInhalationbusiness.industryColistinIpratropiumNebulizers and VaporizersNebulizerAsthmaAcetylcysteineAnti-Bacterial AgentsBronchodilator AgentsNebulizerInhalation solutionsAnesthesiaPediatrics Perinatology and Child HealthIpratropiumColistinTobramycinDrug Therapy Combinationbusinessmedicine.drugJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
researchProduct

Kalziphylaxie: Ischämische Hautnekrosen bei terminaler Niereninsuffizienz

2000

Calciphylaxis is a rare but potentially life-threatening complication in chronic renal failure. It is characterized by ischemic tissue necrosis primarily of the skin. The typical histopathologic finding is microvascular calcification with endovascular fibrosis. Patients typically present with violaceous, mottled and painful lesions which tend to progress to non-healing ulcers and necrosis. Most frequently the lower extremities are involved in a symmetric fashion but the trunk may also be affected. Sepsis from superinfection of the lesions accounts for the high mortality of this disease which is of importance for dermatologists and nephrologists alike. 61-year-old female patient developed le…

Calciphylaxismedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentDermatologymedicine.diseaseDermatologySepsisFibrosisBiopsyMedicineHemodialysisbusinessComplicationCalcificationKidney diseaseDer Hautarzt
researchProduct

Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology.

2021

Abstract Asymptomatic anthracosis is the accumulation of black carbon particles in adult human lungs. It is a common occurrence, but the pathophysiologic significance of anthracosis is debatable. Using in situ high mass resolution matrix-assisted laser desorption/ionization (MALDI) fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometry imaging analysis, we discovered noxious carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines, or aromatic amines, in a series of 330 patients with lung cancer in highly variable and unique patterns. The characteristic nature of carbon-bound exogenous compounds had a strong association wi…

Cancer ResearchLung NeoplasmsNitrosaminesDNA damageCarcinogenesismedicine.disease_causeMass SpectrometryTobacco UseMetabolomeTumor MicroenvironmentMedicineHumansCarcinogenesis; Carcinoma Squamous Cell/chemically induced; Carcinoma Squamous Cell/metabolism; Carcinoma Squamous Cell/pathology; Humans; Idiopathic Pulmonary Fibrosis/chemically induced; Idiopathic Pulmonary Fibrosis/metabolism; Idiopathic Pulmonary Fibrosis/pathology; Lung Neoplasms/chemically induced; Lung Neoplasms/metabolism; Lung Neoplasms/pathology; Mass Spectrometry; Metabolome; Nitrosamines/adverse effects; Polycyclic Aromatic Hydrocarbons/adverse effects; Retrospective Studies; Tobacco Use; Tumor MicroenvironmentPolycyclic Aromatic HydrocarbonsLung cancer610 Medicine & healthRetrospective StudiesAnthracosisLungbusiness.industrymedicine.diseasePathophysiologyIdiopathic Pulmonary Fibrosismedicine.anatomical_structureOncologyTumor progressionCancer researchCarcinoma Squamous CellMetabolome570 Life sciences; biologybusinessCarcinogenesis
researchProduct

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

2014

7022^ Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by dysregulation of the Janus kinase (JAK) pathway resulting in bone marrow fibrosis, splenomegaly, and debilitat...

Cancer ResearchRuxolitinibPathologymedicine.medical_specialtybusiness.industryBone marrow fibrosismedicine.diseasechemistry.chemical_compoundDose findingOncologychemistryPanobinostatCancer researchMedicineIn patientbusinessJanus kinaseMyelofibrosisMyeloproliferative neoplasmmedicine.drugJournal of Clinical Oncology
researchProduct

Bone marrow fibrosis and diagnosis of essential thrombocythemia

2009

However, there are serious issues to beraisedconcerningtheauthors’analysisoftheclinicaldata,thecriteriausedtodiagnoseET,andthequantificationoffibrosis.Altogethertheauthors compared a heterogenous patient database, which included311 patients evaluated for presenting features, 299 for response totherapy,361forcomplicationrates,97forprogressionoffibrosis,andfour for reversal of BM fibrosis, so no single cohort with consistentfeatures was described throughout the study of 361 patients. Forexample, for the analysis of progression of fibrosis, only 97 (12%) oftheoriginal809patientsenteredintheUK-PT1trial

Cancer Researchmedicine.medical_specialtyPathologyessential thrombocythemiabusiness.industryEssential thrombocythemiaMEDLINEBone marrow fibrosismedicine.diseasemyeloproliferative neoplasmsOncologyInternal medicineCohortMedicinePatient databasebusinessBone marrow fibrosi
researchProduct

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI…

2021

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respec…

Cancer Researchmedicine.medical_specialtyRuxolitinib8-item Morisky Medication Adherence ScalePsychometricsTreatment adherenceruxolitiniboral therapiesMedication AdherenceCohort StudiesTreatment complianceInternal medicineSurveys and QuestionnairesNitrilesmedicineHumansIn patientProspective StudiesProspective cohort studyMyelofibrosistreatment compliance8-item Morisky Medication Adherence Scale oral therapies ruxolitinib treatment compliance Adherencebusiness.industryHematologyJanus Kinase 1Janus Kinase 2Interim analysismedicine.disease8-item Morisky Medication Adherence Scale; Adherence; oral therapies; ruxolitinib; treatment compliancePyrimidinesOncologyAdherencePrimary MyelofibrosisPyrazolesObservational studybusinessmedicine.drugLeukemialymphoma
researchProduct

2021

Growth and differentiation factor 15 (GDF15) belongs to the transforming growth factor-β (TGF-β) superfamily of proteins. Glial-derived neurotrophic factor (GDNF) family receptor α-like (GFRAL) is an endogenous receptor for GDF15 detected selectively in the brain. GDF15 is not normally expressed in the tissue but is prominently induced by “injury”. Serum levels of GDF15 are also increased by aging and in response to cellular stress and mitochondrial dysfunction. It acts as an inflammatory marker and plays a role in the pathogenesis of cardiovascular diseases, metabolic disorders, and neurodegenerative processes. Identified as a new heart-derived endocrine hormone that regulates body growth,…

Cardiac fibrosis030204 cardiovascular system & hematologyCatalysisInorganic Chemistry03 medical and health sciencesParacrine signalling0302 clinical medicineNeurotrophic factorsGlial cell line-derived neurotrophic factorMedicinePhysical and Theoretical ChemistryReceptorAutocrine signallingMolecular BiologySpectroscopy030304 developmental biology0303 health sciencesbiologybusiness.industryOrganic ChemistryGeneral Medicinemedicine.disease3. Good healthComputer Science Applicationsbiology.proteinCancer researchGDF15businessTransforming growth factorInternational Journal of Molecular Sciences
researchProduct

Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disea…

2015

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has been associated with increased cardiovascular risk, including coronary artery disease and cardiac dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a new cardiometabolic risk factor. We tested the correlation between epicardial fat, alterations in cardiac geometry and function, and severity of liver damage, in patients with biopsy-proven NAFLD. Methods The anthropometric, biochemical and metabolic features were recorded in 147 consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was measured by echocardiography. Results Epicardial fat was higher in patients w…

Cardiac function curveAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaStatistics as TopicDiastoleEPICARDIAL FATSettore MED/08 - Anatomia PatologicaSeverity of Illness IndexCoronary artery diseaseLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNASH; NAFLD; EPICARDIAL FAT; CARDIAC DYSFUNCTION;Internal medicineNAFLDmedicineHumansSettore MED/12 - GastroenterologiaEjection fractionHepatologybusiness.industryFatty liverNASHHeartMiddle Agedmedicine.diseaseEndocrinologyLiverCardiovascular DiseasesEchocardiographyCardiologyFemaleSteatohepatitisbusinessPericardiumCARDIAC DYSFUNCTION
researchProduct